<DOC>
	<DOCNO>NCT00806819</DOCNO>
	<brief_summary>The trial perform evaluate BIBF 1120 combination standard pemetrexed therapy effective placebo ( inactive capsule ) plus standard pemetrexed therapy patient stage IIIB , IV recurrent NSCLC . Safety information BIBF1120/pemetrexed obtain .</brief_summary>
	<brief_title>Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared Placebo Plus Pemetrexed 2nd Line Nonsquamous NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female patient age 18 year old . 2 . Histologically cytologically confirm Stage IIIB , IV ( accord AJCC ) recurrent non small cell lung cancer ( NSCLC ) ( non squamous histology ) 3 . Relapse failure one first line chemotherapy ( case recurrent disease one additional prior regimen allow adjuvant , neoadjuvant neoadjuvant plus adjuvant therapy ) . 4 . At least one target tumor lesion irradiate within past three month accurately measure magnetic resonance imaging ( MRI ) compute tomography ( CT ) least one dimension ( long diameter record ) great equal 20 mm conventional technique great equal 10 mm spiral CT. 5 . Life expectancy least three month . 6 . Eastern Cooperative Oncology Group ( ECOG ) score 0 1 . 7 . Patient give write informed consent must consistent International Conference Harmonization , Good Clinical Practice ( ICHGCP ) local legislation . Exclusion criterion : 1 . Previous therapy vascular endothelial growth factor ( VEGF ) inhibitor ( bevacizumab ) pemetrexed treatment NSCLC 2 . Treatment investigational drug treatment another clinical trial within past four week start therapy concomitantly trial 3 . Chemotherapy , hormone therapy , immunotherapy monoclonal antibody , treatment tyrosine kinase inhibitor , radiotherapy ( except treatment extremity ) within past four week prior treatment trial drug , i.e. , minimum time elapse since last anticancer therapy first administration BIBF 1120 must four week 4 . Inability stop intake NSAIDS ( non steroidal anti inflammatory drug ) several day 5 . Active brain metastasis ( e.g . stable &lt; 4 week , adequate previous treatment radiotherapy , symptomatic , require treatment anticonvulsant ) . Dexamethasone therapy allow administer stable dose least one month randomisation ) 6 . Radiographic evidence cavitary necrotic tumor 7 . Centrally locate tumor radiographic evidence ( CT MRI ) local invasion major blood vessel 8 . History clinically significant haemoptysis within past 3 month 9 . Therapeutic anticoagulation 10 . History major thrombotic clinically relevant major bleed event past 6 month 11 . Significant cardiovascular disease ( i.e. , hypertension control medical therapy , unstable angina , history myocardial infarction within past 6 month , 12 . Inadequate kidney , liver , blood clot function 13 . Inadequate blood count 14 . Significant weight loss ( &gt; 10 % ) within past 6 week prior treatment present trial 15 . Current peripheral neuropathy great equal Common Terminology Criteria Adverse Events ( CTCAE ) Grade 2 except due trauma 16 . Preexisting ascites ( abdominal fluid collection ) and/or clinically significant pleural effusion ( fluid collection lung chest wall ) 17 . Major injury and/or surgery within past ten day prior start study drug 18 . Incomplete wind heal 19 . Active chronic hepatitis C and/or B infection Additional exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>